P4–417: Incidence and clinical progression of placebo‐treated amyloid‐negative subjects with mild‐to‐moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab. (1st July 2013) - Salloway, Stephen; Sperling, Reisa; Gregg, Keith; Yu, Peng; Joshi, Abhinay; Lu, Ming; Mintun, Mark; Pontecorvo, Michael; Booth, Kevin; Wyman, Bradley; Sun, Jia; Sundell, Karen; et al.